Search

Your search keyword '"Olmez, Omer Fatih"' showing total 146 results
Start Over Author "Olmez, Omer Fatih"
146 results on '"Olmez, Omer Fatih"'

9. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.

Author

Kutlu, Yasin, Dae, Shute Ailia, Yilmaz, Feride, Erdem, Dilek, Sendur, Mehmet Ali Nahit, Akbas, Sinem, Senocak Tasci, Elif, Bas, Onur, Dane, Faysal, Sakin, Abdullah, Kaya, Ali Osman, Aykan, Musa Baris, Ergun, Yakup, Biter, Sedat, Disel, Umut, Korkmaz, Mustafa, Selcukbiricik, Fatih, Kose, Fatih, Olmez, Omer Fatih, and Bilici, Ahmet

Subjects
ADENOCARCINOMA, PATIENT safety, STOMACH tumors, ANTINEOPLASTIC agents, ESOPHAGEAL tumors, RETROSPECTIVE studies, TREATMENT effectiveness, CANCER chemotherapy, METASTASIS, DRUG efficacy, RESEARCH, NIVOLUMAB, PROGRESSION-free survival, EVALUATION
Abstract

Simple Summary: We evaluated the real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. In addition, we identified subgroups that may experience superior outcomes. The median progression-free survival and overall survival were 11.7 months and 18.2 months, respectively, whereas the objective response rate was 70.3%. Our results showed that nivolumab plus chemotherapy is effective and safe for first-line treatment of Turkish patients with HER2-negative advanced gastric, GEJ, or esophageal adenocarcinoma. Patient selection is crucial for optimal outcomes. Future studies are needed to identify predictive biomarkers and treatment strategies to further improve the prognosis of patients. Based on the CheckMate 649 trial, nivolumab plus chemotherapy is the recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated the real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers in Turkey, this study retrospectively reviewed the clinical charts of adult patients diagnosed with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma from 2016 to 2023. This study included 111 patients (54 women, 57 men) with a median age of 58 years. The median progression-free survival (PFS) and overall survival (OS) were 11.7 months and 18.2 months, respectively, whereas the objective response rate (ORR) was 70.3%. Multivariable analyses revealed that previous curative surgery was a favorable independent prognostic factor for both PFS and OS. Conversely, an Eastern Cooperative Oncology Group performance status of 2 emerged as an adverse independent prognostic factor for OS. The safety profile of nivolumab plus chemotherapy was found to be manageable. Our findings support the use of nivolumab plus chemotherapy for the first-line treatment of Turkish patients with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma. Patient selection based on clinical characteristics is crucial for optimizing treatment outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study.

Author

Olmez, Omer Fatih, Bilici, Ahmet, Er, Ozlem, Bisgin, Atil, Sevinc, Alper, Akman, Tulay, Uslu, Ruchan, Mandel, Nil Molinas, Yalcin, Suayib, Teomete, Mehmet, Gorumlu, Gurbuz, Demir, Atakan, Namal, Esat, Alici, Suleyman, Selcukbiricik, Fatih, Bavbek, Sevil, Paksoy, Fatma, Basaran, Gul, Ozer, Leyla, and Sener, Nur

Published
2024
Full Text
View/download PDF

13. Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

Author

Karadurmus, Nuri, Nahit Sendur, Mehmet Ali, Karaca, Burcak, Olmez, Omer Fatih, Hacibekiroglu, Ilhan, Coskun, Hasan Senol, Degirmencioglu, Serkan, Kemal, Yasemin, Kilickap, Saadettin, Sumbul, Ahmet Taner, Aydin, Burc, Turna, Hande, Kaplan, Muhammet Ali, Babacan, Nalan, Demirci, Umut, Ata, Alper, Erdem, Dilek, Ozet, Ahmet, and Abali, Huseyin

Published
2018
Full Text
View/download PDF

18. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Author

Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

19. Major and minor salivary gland cancers: A multicenter retrospective study

Author

Hacioglu, Muhammet Bekir, primary, Erdogan, Bulent, additional, Bardakcı, Murat, additional, Algın, Efnan, additional, Gulbagcı, Burcu, additional, Hacibekiroglu, Ilhan, additional, Hamdard, Jamshid, additional, Olmez, Omer Fatih, additional, Akkus, Hadi, additional, Oksuzoglu, Berna, additional, Goksu, Sema Sezgin, additional, Dae, Shute Ailia, additional, Sumbul, Ahmet Taner, additional, Ugraklı, Muzaffer, additional, Karaagac, Mustafa, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Ozer, Ozden, additional, Yavuzsen, Tugba, additional, Arıkan, Rukiye, additional, Köstek, Osman, additional, Atcı, Muhammed Mustafa, additional, Sakin, Abdullah, additional, Deligonul, Adem, additional, Bayır, Duygu, additional, Dincer, Murat, additional, Unsal, Oktay, additional, Yazıcı, Ozan, additional, Zeynelgil, Esra, additional, Gulmez, Ahmet, additional, Harputluoglu, Hakan, additional, Erol, Cihan, additional, Sendur, Mehmet Ali Nahit, additional, Aytekin, Aydin, additional, Akagunduz, Baran, additional, Oner, Irem, additional, Er, Ozlem, additional, Oztosun, Bugra, additional, Gumus, Mahmut, additional, Biricik, Fatih Selcuk, additional, Aykan, Musa Baris, additional, Karadurmus, Nuri, additional, Degerli, Ezgi, additional, Demirci, Nebi Serkan, additional, Turkmen, Esma, additional, Şakalar, Teoman, additional, Secmeler, Saban, additional, Tanrıverdi, Ozgur, additional, Alkan, Ali, additional, Kemal, Yasemin, additional, Cil, Ibrahim, additional, Unal, Caglar, additional, Iriagaç, Yakup, additional, Alan, Ozkan, additional, Balli, Sevinc, additional, Urun, Yuksel, additional, Ozcan, Erkan, additional, Turhal, Nazım Serdar, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

20. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Author

Bilici, Ahmet, primary, Olmez, Omer Fatih, additional, Kaplan, Muhammed Ali, additional, Oksuzoglu, Berna, additional, Sezer, Ahmet, additional, Karadurmus, Nuri, additional, Cubukcu, Erdem, additional, Sendur, Mehmet Ali Nahit, additional, Aksoy, Sercan, additional, Erdem, Dilek, additional, Basaran, Gul, additional, Cakar, Burcu, additional, Shbair, Abdallah T. M., additional, Arslan, Cagatay, additional, Sumbul, Ahmet Taner, additional, Sezgin Goksu, Sema, additional, Karadag, Ibrahim, additional, Cicin, Irfan, additional, Gumus, Mahmut, additional, Selcukbiricik, Fatih, additional, Harputluoglu, Hakan, additional, and Demirci, Umut, additional

Published
2023
Full Text
View/download PDF

26. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Author

Tural, Deniz, primary, Arslan, Cagatay, additional, Selcukbiricik, Fatih, additional, Olmez, Omer Fatih, additional, Akar, Emre, additional, Erman, Mustafa, additional, Ürün, Yüksel, additional, Erdem, Dilek, additional, Karadurmus, Nuri, additional, and Kilickap, Saadettin, additional

Published
2022
Full Text
View/download PDF

28. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

30. Effects of Cytoreductive Nephrectomy on Nivolumab Outcomes in Patients with Metastatic Clear Cell Renal Carcinoma: A Retrospective Observational Real-Life Data of Turkish Oncology Group

Author

Ocak, Birol, primary, Sahin, Ahmet Bilgehan, additional, Ertürk, Ismail, additional, Korkmaz, Mustafa, additional, Erdem, Dilek, additional, Cakıroglu, Umut, additional, Karaca, Mustafa, additional, Dirican, Ahmet, additional, Olmez, Omer Fatih, additional, Aydın, Sabin Göktaş, additional, Gökyer, Ali, additional, Küçükarda, Ahmet, additional, Gülmez, Ahmet, additional, Yumuk, Perran Fulden, additional, Demircan, Nazim Can, additional, Oyman, Abdilkerim, additional, Sakalar, Teoman, additional, Karataş, Fatih, additional, Demir, Hacer, additional, Yasin, Ayse Irem, additional, Deligönül, Adem, additional, Dakiki, Bahar, additional, Goktug, Mehmet Refik, additional, Avcı, Okan, additional, Tacar, Seher Yildiz, additional, Turhal, Nazım Serdar, additional, Deniz, Gulhan Ipek, additional, Kacan, Turgut, additional, Cubukcu, Erdem, additional, and Evrensel, Türkkan, additional

Published
2022
Full Text
View/download PDF

32. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Author

Bilici, Ahmet, primary, Olmez, Omer Fatih, additional, Sezer, Ahmet, additional, Oksuzoglu, Berna, additional, Kaplan, Muhammet Ali, additional, Karadurmus, Nuri, additional, Cubukcu, Erdem, additional, Sendur, Mehmet A.N., additional, Aksoy, Sercan, additional, Erdem, Dilek, additional, Basaran, Gul, additional, Cakar, Burcu, additional, Seker, Mesut, additional, Arslan, Cagatay, additional, Sezgin Goksu, Sema, additional, Cicin, Irfan, additional, Gumus, Mahmut, additional, Selcukbiricik, Fatih, additional, Harputluoglu, Hakan, additional, and Helvaci, Kaan, additional

Published
2022
Full Text
View/download PDF

33. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study)

Author

Bilici, Ahmet, Olmez, Omer Fatih, Sezer, Ahmet, Oksuzoglu, Berna, Kaplan, Muhammet Ali, Karadurmus, Nuri, and Cubukcu, Erdem

Abstract

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK, [No Abstract Available], Amer Soc Clin Oncol, Roche Pharmaceuticals, Roche Pharmaceuticals.

Published
2022

37. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Author

Bilici, Ahmet, primary, Uysal, Mukremin, additional, Menekse, Serkan, additional, Akin, Semih, additional, Yildiz, Fatih, additional, Turan, Merve, additional, Sezgin Goksu, Sema, additional, Beypinar, Ismail, additional, Sakalar, Teoman, additional, Değirmenci, Mustafa, additional, Erdem, Dilek, additional, Basaran, Gul, additional, Olmez, Omer Fatih, additional, Avci, Nilufer, additional, Tural, Deniz, additional, Sakin, Abdullah, additional, Turker, Sema, additional, Demir, Atakan, additional, Temiz, Suleyman, additional, Kaplan, Muhammed Ali, additional, Dogan, Mutlu, additional, Tanriverdi, Ozgur, additional, Bilgetekin, Irem, additional, Cinkir, Havva Yesil, additional, Acikgoz, Ozgur, additional, Paydas, Semra, additional, Uslu, Ruchan, additional, and Turhal, Serdar, additional

Published
2021
Full Text
View/download PDF

39. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

Author

Tural, Deniz, primary, Olmez, Omer Fatih, additional, Sümbül, Ahmet Taner, additional, Artac, Mehmet, additional, Ozhan, Nail, additional, Akar, Emre, additional, Cakar, Burcu, additional, Kostek, Osman, additional, Ekenel, Meltem, additional, Coskun, Hasan Senol, additional, Selcukbiricik, Fatih, additional, Keskin, Özge, additional, Paksoy Turkoz, Fatma, additional, oruc, kerem, additional, Bayram, Selami, additional, Yilmaz, Ugur, additional, Bilgetekin, Irem, additional, Yildiz, Birol, additional, Sendur, Mehmet Ali Nahit, additional, and Erman, Mustafa, additional

Published
2021
Full Text
View/download PDF

40. Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients With Extensive-Stage Small Cell Lung Carcinoma Treated with Atezolizumab in Combination with Chemotherapy: Single Center Experience

Author

Kutlu, Yasin, primary, Aydin, Sabin Goktas, additional, Bilici, Ahmet, additional, Oven, Bala Basak, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, Hamdard, Jamshid, additional, and Karci, Ebru, additional

Published
2021
Full Text
View/download PDF

41. Triple‐negative breast cancer presented with metastasis to the heart as first sign of recurrence

Author

Bayramgil, Ayberk, primary, Bilici, Ahmet, additional, Hamdard, Jamshid, additional, Acikgoz, Ozgur, additional, Seker, Mehmet, additional, Kilicaslan, Fethi, additional, Koksal, Cengiz, additional, Buyukpinarbasili, Nur, additional, Mammadov, Elkhan, additional, Goktas Aydin, Sabin, additional, Olmez, Omer Fatih, additional, and Yildiz, Ozcan, additional

Published
2020
Full Text
View/download PDF

42. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Author

Peled, Nir, primary, Gillis, Roni, additional, Kilickap, Saadettin, additional, Froesch, Patrizia, additional, Orlov, Sergei, additional, Filippova, Elena, additional, Demirci, Umut, additional, Christopoulos, Petros, additional, Cicin, Irfan, additional, Basal, Fatma Bugdayci, additional, Yilmaz, Cengiz, additional, Fedor, Moiseenko, additional, Korkmaz, Taner, additional, Paydas, Semra, additional, Gautschi, Oliver, additional, Zirtiloglu, Alisan, additional, Eralp, Yesim, additional, Cinkir, Havva Yesil, additional, Sezer, Ahmet, additional, Erman, Mustafa, additional, Tural, Deniz, additional, Turna, Hande, additional, Mazieres, Julien, additional, Dudnik, Elizabeth, additional, Reguart, Noemi, additional, Camidge, David Ross, additional, Ng, Terry L., additional, Şenler, Filiz Çay, additional, Beypınar, İsmail, additional, Yazılıtaş, Doğan, additional, Demirkazık, Ahmet, additional, Karaoğlu, Aziz, additional, Okutur, Kerem, additional, Coşkun, Hasan Şenol, additional, Şendur, Mehmet Ali Nahit, additional, Isikdogan, Abdurrahman, additional, Cabuk, Devrim, additional, Yumuk, Perran Fulden, additional, Yıldız, Ibrahim, additional, Kaplan, M. Ali, additional, Özyılkan, Özgür, additional, Öztop, İlhan, additional, Olmez, Omer Fatih, additional, Aydin, Kübra, additional, Aydıner, Adnan, additional, Meydan, Nezih, additional, Grinberg, Roxana Denisa, additional, and Roisman, Laila C., additional

Published
2020
Full Text
View/download PDF

43. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.

Author

Bilici, Ahmet, Uysal, Mukremin, Menekse, Serkan, Akin, Semih, Yildiz, Fatih, Turan, Merve, Sezgin Goksu, Sema, Beypinar, Ismail, Sakalar, Teoman, Değirmenci, Mustafa, Erdem, Dilek, Basaran, Gul, Olmez, Omer Fatih, Avci, Nilufer, Tural, Deniz, Sakin, Abdullah, Turker, Sema, Demir, Atakan, Temiz, Suleyman, and Kaplan, Muhammed Ali

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, EPIDERMAL growth factor receptors, MULTIVARIATE analysis, METASTASIS, CELL receptors, CANCER patients, EVEROLIMUS, EXEMESTANE, HORMONE receptor positive breast cancer, PROGESTERONE receptors
Abstract

This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Author

Kilickap, Saadettin, Ozturk, Akin, Karadurmus, Nuri, Korkmaz, Taner, Yumuk, Perran Fulden, Cicin, Irfan, Paydas, Semra, Cilbir, Ebru, Sakalar, Teoman, Uysal, Mukremin, Yesil Cinkir, Havva, Uskent, Necdet, Demir, Necla, Sakin, Abdullah, Dursun, Oldac Uras, Aver, Birkan, Turhal, Nazim Serdar, Keskin, Serkan, Tural, Deniz, Eralp, Yesim, Bugdayci Basal, Fatma, Yasar, Hatime Arzu, Sendur, Mehmet Ali Nahit, Demirci, Umut, Cubukcu, Erdem, Karaagac, Mustafa, Cakar, Burcu, Tatli, Ali Murat, Yetisyigit, Tarkan, Urvay, Semiha, Gursoy, Pinar, Oyan, Basak, Turna, Zeynep Hande, Isikdogan, Abdurrahman, Olmez, Omer Fatih, Yazici, Ozan, Cabuk, Devrim, Seker, Mehmet Metin, Unal, Olcun Umit, Meydan, Nezih, Okutur, Sadi Kerem, Tunali, Didem, and Erman, Mustafa

Abstract

To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2–16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers—a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.

Published
2024
Full Text
View/download PDF

45. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

Author

Bilici, Ahmet, primary, Selcukbiricik, Fatih, additional, Seker, Mesut, additional, Oven, Basak B., additional, Olmez, Omer Fatih, additional, Yildiz, Ozcan, additional, Olmuscelik, Oktay, additional, Hamdard, Jamshid, additional, Acikgoz, Ozgur, additional, Cakir, Asli, additional, Kapran, Yersu, additional, Balik, Emre, additional, and Oncel, Mustafa, additional

Published
2019
Full Text
View/download PDF

48. Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade.

Author

Olmez, Omer Fatih, Kinikoglu, Oguzcan, Yilmaz, Nesrin Helvacı, Bilici, Ahmet, Cubukcu, Erdem, Seker, Mehmet, Cakir, Tansel, Yildiz, Ozcan, and Hamdard, Jamshid

Subjects
*THERAPEUTIC use of immunoglobulins, *PREDNISOLONE, *AUTOANTIBODIES, *BREAST tumors, *CANCER chemotherapy, *GENE expression, *IMMUNOTHERAPY, *ONCOGENES, *SERUM, *OPSOCLONUS-Myoclonus syndrome, *THERAPEUTICS
Abstract

Paraneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus–myoclonus–ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%–25% of breast cancer and is associated with poor prognosis. There are a few reports of paraneoplastic neurological syndrome associated with HER2-positive breast cancer in the literature, of which most are anti-Yo-associated paraneoplastic neurological syndrome. We present herein the case of a female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome. Following the diagnosis of paraneoplastic syndrome, chemotherapy with dual HER2 blockade and immunomodulating treatment including intravenous immunoglobulin and oral prednisolone were administered. Although the patient was negative for serum anti-Ri antibodies, there was partial clinical improvement and her neurological deficit persisted. To our knowledge, this is the first case report of female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome and treated with dual HER2 blockade. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results